Mdxhealth Highlights Data from Oxford’s ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026

Key Takeaways:

• The GPS test helps predict the likelihood of adverse outcomes in prostate cancer.
• Oxford’s ProMPT Study provided the foundational data for these findings.
• Mdxhealth shared the research at the EAU 2026 event.
• The test appears applicable across multiple clinical treatments.
• This development may influence how physicians manage prostate cancer cases.

Research Presented at EAU 2026

Mdxhealth’s announcement at EAU 2026 put a spotlight on the latest findings in prostate cancer research. As part of the conference’s mission to showcase leading scientific breakthroughs, the study results from Oxford’s ProMPT Study drew significant attention to potential advances in how prostate cancer might be managed.

Genomic Prostate Score (GPS) Test Findings

At the core of the presentation was the Genomic Prostate Score (GPS) test, which offers a way to predict adverse outcomes among prostate cancer patients. Sourced from the extensive data in Oxford’s ProMPT Study, the GPS test findings suggest the possibility of helping clinicians refine their treatment decisions. By leveraging the GPS test, different treatment settings can be evaluated for each patient, aiming for more individualized approaches.

Implications for Prostate Cancer Management

These results underline the critical role of genomic testing in the future of prostate cancer care. Mdxhealth has emphasized that, by harnessing these insights, physicians can potentially identify which patients are at higher risk of negative treatment outcomes. Although full details of the study remain proprietary beyond paid plans, the broad conclusions indicate a step toward more targeted and informative care strategies, underscoring the importance of predictive diagnostics in modern medical practice.